Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Novartis has officially petitioned the Supreme Court in an ongoing effort to protect Gilenya from generic rivals for at least another several years.
The Swiss …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.